Browse diseases

…ies have shown success in hematologic malignancies, efficacy in solid tumors has been limited, partly due to T-cell exhaustion within the im…

… major barrier to realizing their full therapeutic potential in solid tumors. Increasing evidence suggests that maintenance of a stem-like N…

…systems we currently employ. To address this issue we generated Acute Myeloid Leukemia (AML) and Ovarian Cancer (OC) models using three different mous…

…nd T cell engagers (TCEs) have demonstrated clinical success in hematological malignancies, however, many compelling TCE targets have remained out of reac…

…nd T cell engager bispecifics, have had limited success against solid tumors. Hypotheses proposed to explain such limited success include an…

…ed T cell engagers (TCEs) have demonstrated clinical success in solid tumors, including DLL3×CD3, GP100×CD3, and STEAP1×CD3 formats. However…

…erged as an advanced and highly effective approach for treating hematologic malignancies with its scope rapidly expanding to encompass diverse applicati…

…c potential of adoptive NK cell transfer remains constrained in solid tumors due to insufficient tumor infiltration efficiency. Developing a…

…strated efficacy across a range of common solid tumors and some hematopoietic malignancies. Despite these groundbreaking successes, the clinical developme…

…ibitors and T cell therapies have mediated durable responses in hematologic malignancies and select solid tumors, most patients still relapse or fail to…